Methods and compositions for improving sleep
View Patent ↗Compositions suitable for oral use (e.g., oral thin film) containing various excipients and a combination of melatonin, caryophyllene, GABA, L-theanine, and vitamin B 6 . Methods of using the composition, e.g., in the treatment of a sleeping disorder, as well as methods of manufacturing the composition are also included.
1. A method of improving sleep in a human subject, the method comprising orally administering to the human subject in need thereof an oral thin film having a mass of about 110-130 mg, the oral thin film comprising:
(i) 1.5±0.5 mg Nacetyl-5-methoxy tryptamine (melatonin),
(ii) 15±5 mg (−)-β-caryophyliene (caryophyllene),
(iii) 7.5±3 mg 4-aminobutanoic acid (GABA),
(iv) 12±6 mg L-γ-glutamylethylamide (L-theanine),
(v) 3±2 mg pyridoxine (vitamin B6),
(vi) 29±15 mg in the aggregate of at least one of binder, thickening agent, and gelling agent, comprising pectin and microcrystalline cellulose,
(vii) 10±4 mg plasticizer comprising glycerin,
(viii) 2±1 mg lipid comprising lecithin (soy) and deodorized cocoa butt
(ix) 8±5 mg flavoring agent comprising natural flavors, and
(x) 8±5 mg sweetener comprising sucralose and acesulfame potassium.
2. The method of claim 1 , wherein the method of improving the sleep in the subject comprises at least one of improving the quality of sleep and increasing the length of time of sleep.
3. The method of claim 1 , wherein the method of improving the sleep in the subject comprises treating at least one of a sleeping disorder (somnipathy), dyssomnias, and insomnia.
4. The method of claim 1 , wherein the method of improving the sleep in the subject comprises treating a sleeping disorder (somnipathy) characterized by at least one of:
(i) difficulty getting to sleep,
(ii) difficulty remaining asleep,
(iii) sleepiness upon awakening,
(iv) significant amount of non-REM sleep, and
(i) early awakenings.
5. The method of claim 1 , wherein the method of improving the sleep in the subject comprises at least one of:
(i) decreasing sleep onset latency,
(ii) increasing total time slept,
(iii) decreasing sleepiness upon awakening,
(iv) promoting a deep sleep,
(v) promoting REM sleep, and
(vi) preventing early awakenings.
6. The method of claim 1 , wherein the oral film is placed on the tongue of the subject.
7. The method of claim 1 , wherein the oral film is orally administered up to about 30 minutes prior to bedtime.
8. The method of claim 1 , wherein 1-2 of the oral films are orally administered up to about 30 minutes prior to bedtime.
9. The method of claim 1 , wherein substances (i)-(v) are delivered enterally.
10. The method of claim 1 , wherein substances (i)-(v) are delivered sublingually.
11. The method of claim 1 , wherein substances (i)-(v) are delivered buccally.
12. The method of claim 1 , wherein substances (i)-(v) are delivered transmucosally.
13. The method of claim 1 , wherein the oral thin film has a thickness of from about 0.1 mils to about 30 mils and wherein the oral thin film completely dissolves in the oral cavity within about 90 seconds after orally administering to the human subject.
14. The method of claim 1 , wherein the oral thin film has a thickness of from about 0.1 mils to about 30 mils and wherein the oral thin film completely dissolves in the oral cavity within about 60 seconds after orally administering to the human subject.
15. The method of claim 1 , wherein 1-2 of the oral thin film (OTFs) are administered up to about 15 minutes prior to bedtime.
16. The method of claim 1 , wherein oral thin film (OTF) that dissolves in the mouth within about 120 seconds after orally administering to the human subject.
17. The method of claim 1 , wherein the oral thin film (OM has the following dimensions: 44±3 mm x 22±1 mm x 0.1.2±0.01 mm.
18. The method of claim 1 , wherein the oral thin film (OTF) has the following dimensions: 44±6 mm x 22±3 mm x 0.12±0.02 mm.
19. The method of claim 1 , which is a short-term treatment of insomnia characterized by difficulties with sleep initiation and excessive sleepiness upon awakening.
20. The method of claim 1 , wherein 1-2 of the oral thin film (OTFs) are administered up to about 30 minutes prior to bedtime.
21. The method of claim 1 , wherein the oral thin film (OTF) dissolves in the mouth within about 30 seconds after orally administering to the human subject.
22. The method of claim 1 , wherein the oral thin film further comprises water.